Oncology News | pharmaphorum

News

AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

News

Merck & Co's Keytruda fails in first line bladder cancer

Merck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Keytruda failed to outperform chemotherapy in this lucrative indication.

News

Close-up image of a firm handshake between two colleagues

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

News

AZ reportedly mulls biggest-ever pharma merger with Gilead

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <

News

AZ to work with Accent on RNA-modifying protein tech in canc...

AstraZeneca is to work with US biotech Accent Therapeutics on therapies targeting RNA-modifying proteins (RMPs) for treatment of cancer.

News

Sanofi's multiple myeloma drug approved in EU

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex

AbbVie forges $3.9 billion oncology alliance with Genmab

Merck & Co's Keytruda fails in first line bladder cancer

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AZ reportedly mulls biggest-ever pharma merger with Gilead

AZ to work with Accent on RNA-modifying protein tech in canc...

Sanofi's multiple myeloma drug approved in EU

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks